Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventional

Outcomes With Multi Parametric MRI (mpMRI) Compared to Diagnostic Transurethral Resection of Bladder Tumor (TURBT) in Patients With Suspected Muscle-Invasive Bladder Cancer - a Pilot Study

NCT ID: NCT06335667Sponsor: University of California, IrvineLast updated: 2026-05-04

Summary

This is a pilot, single arm, prospective study that aims to validate the accuracy of the VI-RADS score obtained via multi-parametric magnetic resonance imaging (mpMRI) compared to pathologic cancer stage obtained via diagnostic transurethral bladder tumor resection (TURBT) as well as compare the clinical and quality of life outcomes between these diagnostic modalities in patients with suspected muscle-invasive bladder cancer (MIBC).

Arms & interventions

  • Diagnostic TestmpMRI + Diagnostic TURBT

    mpMRI in addition to the TURBT surgical procedure

Outcome measures

Primary

  • Incidence of concordance between VI-RADS score of 4 or 5 (i.e. muscular propria is likely or very likely) on mpMRI and pathologic muscularis propria invasion (i.e. pT2 tumor stage) on diagnostic TURBT.

    VI-RADS is a five-point scoring system developed to standardize imaging and reporting of bladder tumor invasiveness on mpMRI. It predicts the degree of possible muscular propria invasion ("muscle-invasiveness") of bladder tumors. Once diagnostic TURBT is performed, the VI-RADS score from mpMRI will be compared to the pathologic tumor (T) stage from a diagnostic TURBT to assess for concordance.

    Time frame: Up to 1 year

Secondary

  • Progression free survival (PFS) with mpMRI compared to diagnostic TURBT

    Time frame: up to 5 years

  • Time from intervention that determines invasiveness of bladder tumors (i.e. diagnostic TURBT versus mpMRI) to initiation of cancer-directed therapy

    Time frame: up to 5 years

  • Time from initial cystoscopy to intervention that determines invasiveness of bladder tumors (i.e diagnostic TURBT versus mpMRI).

    Time frame: up to 5 years

  • Incidence of adverse events with mpMRI versus diagnostic TURBT.

    Time frame: up to 5 years

  • Patient Quality of Life with mpMRI versus diagnostic TURBT.

    Time frame: up to 5 years

  • Incidence of repeat TURBT.

    Time frame: up to 5 years

  • Diagnostic healthcare expenditure with mpMRI versus diagnostic TURBT

    Time frame: up to 5 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Age 18 years old or greater at the time of consent. * Suspected muscle-invasive bladder cancer by tumor appearance on initial routine cystoscopy as determined by the UCI-affiliated provider performing this procedure. * ECOG Performance Status of 0-3. * Patients must have the ability to understand and the willingness to sign a written informed consent document (prior to the initiation of the study and any study procedures). * Patients must be willing and able to comply with the scheduled visits, imaging plan, follow up plan, and other specified study procedures in the opinion of the Investigator. Exclusion Criteria: * Prior TURBT within 120 days of study entry. * Prior therapy for bladder cancer within 180 days of study entry. * Inability to tolerate mpMRI or associated contrast. * Inability to tolerate TURBT or associated anesthesia. * ECOG Performance Status of 4. * Female patient who is known to be pregnant or breastfeeding.

Study locations (1)

Chao Family Comprehensive Cancer Center University of California, Irvine

Orange, California, 92868

Recruiting
Nataliya Mar, MD · Contact
1-877-827-8839ucstudy@uci.edu
mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer | Cancerify